NBTX Key Statistics, Chart & Performance
The current stock price of NBTX is 21.52 USD. In the past month the price decreased by -4.99%. In the past year, price increased by 517.5%.
NBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NBTX. When comparing the yearly performance of all stocks, NBTX is one of the better performing stocks in the market, outperforming 99.32% of all stocks.
NBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NBTX. NBTX may be in some trouble as it scores bad on both profitability and health.
NBTX Financial Highlights
Over the last trailing twelve months NBTX reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -47.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.32% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBTX Forecast & Estimates
12 analysts have analysed NBTX and the average price target is 27.05 USD. This implies a price increase of 25.71% is expected in the next year compared to the current price of 21.52.
For the next year, analysts expect an EPS growth of 46.17% and a revenue growth 24.15% for NBTX
NBTX Ownership
About NBTX
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
NANOBIOTIX SA - ADR
60 rue de Wattignies
Paris ILE-DE-FRANCE 75012 FR
CEO: Dr. Laurent Levy
Employees: 103
Phone: 33140260470
NANOBIOTIX SA - ADR / NBTX FAQ
What does NANOBIOTIX SA - ADR do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Can you provide the latest stock price for NANOBIOTIX SA - ADR?
The current stock price of NBTX is 21.52 USD. The price increased by 2.77% in the last trading session.
What is the dividend status of NANOBIOTIX SA - ADR?
NBTX does not pay a dividend.
What is the ChartMill rating of NANOBIOTIX SA - ADR stock?
NBTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about NANOBIOTIX SA - ADR (NBTX) stock?
12 analysts have analysed NBTX and the average price target is 27.05 USD. This implies a price increase of 25.71% is expected in the next year compared to the current price of 21.52.
What is the market capitalization of NBTX stock?
NANOBIOTIX SA - ADR (NBTX) has a market capitalization of 1.04B USD. This makes NBTX a Small Cap stock.
What is the next earnings date for NBTX stock?
NANOBIOTIX SA - ADR (NBTX) will report earnings on 2026-03-31, after the market close.